Ceregene Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 30

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $2.71M

Ceregene General Information

Description

Developer of treatments for neurodegenerative disorders. The company is a biotechnology enterprise ocused on the treatment of major neurodegenerative disorders using the delivery of nervous system growth factors. Its clinical programs include CERE-110, an AAV2-based vector expressing nerve growth factor, for the treatment of Alzheimer's disease; and CERE-120, in trials as a treatment for Parkinson's disease. The company also has two treatments - CERE-135 and CERE-140 - in preclinical development for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and ocular diseases, respectively.

Contact Information

Website
www.ceregene.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 9381 Judicial Drive
  • Suite 130
  • San Diego, CA 92121
  • United States
+1 (858)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Drug Delivery
Acquirer
Sangamo Therapeutics
Vertical(s)
Life Sciences
Corporate Office
  • 9381 Judicial Drive
  • Suite 130
  • San Diego, CA 92121
  • United States
+1 (858)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ceregene Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 02-Oct-2013 $2.71M Completed Clinical Trials - Phase 2
7. Later Stage VC 03-Apr-2012 Completed Generating Revenue
6. Later Stage VC (Series D) 11-Nov-2010 Completed Generating Revenue
5. Grant 22-Jun-2010 Completed Generating Revenue
4. Grant 01-Jan-2008 Completed Generating Revenue
3. Later Stage VC (Series C) 22-Jun-2007 Completed Generating Revenue
2. Early Stage VC (Series B) 13-Aug-2004 $19.7M $30.2M Completed Startup
1. Early Stage VC (Series A) 01-Jan-2001 $10.5M $10.5M Completed Startup
To view Ceregene’s complete valuation and funding history, request access »

Ceregene Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of treatments for neurodegenerative disorders. The company is a biotechnology enterprise ocused on the treatme
Biotechnology
San Diego, CA
30 As of 2017

Burlington, MA
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ceregene Competitors (46)

One of Ceregene’s 46 competitors is Minerva Neurosciences, a Formerly VC-backed company based in Burlington, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Minerva Neurosciences Formerly VC-backed Burlington, MA
Vertex Pharmaceuticals Formerly VC-backed Boston, MA
Kala Bio Formerly VC-backed Arlington, MA
Bionomics Formerly VC-backed Sydney, Australia
NexImmune Formerly VC-backed Gaithersburg, MD
You’re viewing 5 of 46 competitors. Get the full list »

Ceregene Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ceregene Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alta Partners Venture Capital Minority
California Technology Ventures Venture Capital Minority
Cell Genesys Corporation Minority
Hamilton BioVentures Venture Capital Minority
MPM BioImpact Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Ceregene Acquisitions (1)

Ceregene’s most recent deal was a Merger/Acquisition with Salk-ALS Gene Therapy Tech. The deal was made on 09-Mar-2009.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Salk-ALS Gene Therapy Tech 09-Mar-2009 Merger/Acquisition Other Commercial Services
To view Ceregene’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Ceregene FAQs

  • When was Ceregene founded?

    Ceregene was founded in 2000.

  • Where is Ceregene headquartered?

    Ceregene is headquartered in San Diego, CA.

  • What is the size of Ceregene?

    Ceregene has 30 total employees.

  • What industry is Ceregene in?

    Ceregene’s primary industry is Biotechnology.

  • Is Ceregene a private or public company?

    Ceregene is a Private company.

  • What is the current valuation of Ceregene?

    The current valuation of Ceregene is .

  • What is Ceregene’s current revenue?

    The current revenue for Ceregene is .

  • How much funding has Ceregene raised over time?

    Ceregene has raised $69.8M.

  • Who are Ceregene’s investors?

    Alta Partners, California Technology Ventures, Cell Genesys, Hamilton BioVentures, and MPM BioImpact are 5 of 7 investors who have invested in Ceregene.

  • Who are Ceregene’s competitors?

    Minerva Neurosciences, Vertex Pharmaceuticals, Kala Bio, Bionomics, and NexImmune are some of the 46 competitors of Ceregene.

  • When was Ceregene acquired?

    Ceregene was acquired on 02-Oct-2013.

  • Who acquired Ceregene?

    Ceregene was acquired by Sangamo Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »